Journal
Journal of Clinical Oncology
Publication Date
5-1-2024
Volume
42
Issue
13
First Page
1472
Last Page
1476
Document Type
Open Access Publication
DOI
10.1200/JCO.23.02266
Rights and Permissions
Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Ding L, Schmid AN, Navarro WH, Kwiatkowski DJ, Dickson MA. Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update. J Clin Oncol. 2024 May 1;42(13):1472-1476. doi: 10.1200/JCO.23.02266. © 2024 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/
Recommended Citation
Wagner, Andrew J; Ravi, Vinod; Riedel, Richard F; Ganjoo, Kristen; Van Tine, Brian A; Chugh, Rashmi; Cranmer, Lee; Gordon, Erlinda M; Hornick, Jason L; Du, Heng; Ding, Li; Schmid, Anita N; Navarro, Willis H; Kwiatkowski, David J; and Dickson, Mark A, "Phase II trial of nab- sirolimus in patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-term efficacy and safety update." Journal of Clinical Oncology. 42, 13. 1472 - 1476. (2024).
https://digitalcommons.wustl.edu/oa_4/4114
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
